TGTX
TG TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
+
Peers tracked
11
U.S. public peers
Grade Position
Above peers
vs peer average
TGTX vs peer average
72/100
TGTX vs. peer average (B vs. C)
Grade spread
A 1 · B 3 · C 1 · D 3 · F 3
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
NVS is the first available peer comparator.
Novartis' Kesimpta is an approved subcutaneous CD20 therapy for relapsing multiple sclerosis, making it a close convenience and competitive comparator to subcutaneous BRIUMVI. [Novartis Kesimpta prescribing information](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf)
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
TGTX
TG Therapeutics
NVS
Novartis
Grade
B
B
Momentum
85
30
Value
59
64
Sentiment
67
71
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs NVS
TGTX / NVS
Grade Position
Above peers
TGTX vs. peer average (B vs. C)
72/100
Momentum
85
TGTXValue
59
NVSSentiment
67
NVSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs TGTX
NVS is the first peer returned for this comparison set.